This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Insulin Action in Individuals With Type 2 Diabetes by Natural Fatty Acids or the Medication Pioglitazone

This study has been completed.
Sponsor:
Collaborator:
Takeda
Information provided by (Responsible Party):
Meredith Hawkins, Albert Einstein College of Medicine, Inc.
ClinicalTrials.gov Identifier:
NCT00179400
First received: September 13, 2005
Last updated: June 30, 2017
Last verified: June 2017
  Purpose
Doctors are studying natural oils as potential therapies for type 2 diabetes. Animal studies have suggested promising results using EPA (found in fish oils) to improve insulin action and lower blood sugar levels.

Condition Intervention
Type 2 Diabetes Mellitus Drug: Pioglitazone/EPA Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Role of Acute Combined Peroxisome Proliferator-Activated Receptors (PPAR) Alpha and Gamma Stimulation on Insulin Action in Humans

Resource links provided by NLM:


Further study details as provided by Meredith Hawkins, Albert Einstein College of Medicine, Inc.:

Primary Outcome Measures:
  • Whole body in vivo glucose turnover [ Time Frame: 6-hour ]
    Measured during 6-hour normoglycemic (90 mg/dl) stepped hyperinsulinemic clamp studies


Enrollment: 18
Actual Study Start Date: December 2000
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Pioglitazone Drug: Pioglitazone/EPA
Placebo Comparator: Placebo Drug: Placebo

Detailed Description:

PARTICIPATION INCLUDES: Participation in the studies includes taking study capsules for up to 21 days, keeping a meal diary, and up to four overnight hospital stays. During the hospital visits, an IV will be placed in each arm, and small amounts of muscle and fat tissue will be removed (with minimal discomfort).

COMPENSATION: Compensation of $400 per study is provided (or up to $1,600 for completing all studies)

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Type 2 subjects with an A1c over 8.%

Exclusion Criteria:

Those with bleeding disorders including GERD, PUD, any GI bleeding; High blood pressure, and anyone with a history of Coronary Artery Disease or exertional chest pain

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00179400

Locations
United States, New York
Albert Einstein College of Medicine
The Bronx, New York, United States, 10461
Sponsors and Collaborators
Albert Einstein College of Medicine, Inc.
Takeda
Investigators
Principal Investigator: Meredith Hawkins, MD Albert Einstein College of Medicine, Inc.
  More Information

Responsible Party: Meredith Hawkins, Professor, Albert Einstein College of Medicine, Inc.
ClinicalTrials.gov Identifier: NCT00179400     History of Changes
Other Study ID Numbers: 2000-200
Study First Received: September 13, 2005
Last Updated: June 30, 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pioglitazone
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 18, 2017